When selling a clinical trial site, many owners focus solely on the amount they’ll receive, but the real key is understanding the multiplier that determines your valuation. In M&A transactions, hitting the right EBITDA threshold—such as $3M, $10M, or $25M—can significantly increase your multiplier, turning a 6X valuation into 10X or more. While some claim multipliers as high as 26X, the reality is more complex.

Beyond valuation, choosing the right private equity partner is just as critical. Do they want a standalone site, or will you be part of a network? Will you need to align with new processes or teams? Is your payout immediate, or will some be deferred? Many sellers are caught off guard when the check they expected never arrives as planned.

If you're considering an M&A transaction, don't just focus on the final price—understand the full process. We help clinical research sites navigate these deals strategically. Call, click, or email to learn more!

Support the show